Kicking off the proteomics track at the Beyond Genome conference in late June, Stephen Naylor from MIT’s CSBi program introduced a number of challenges he sees facing proteomics scientists. The good news, he noted, is that proteomics is getting more attention from more researchers, noting that the majority of talks and papers at this year’s ASMS meeting involved proteomics. But there’s some bad news too, he said, including what he called the “graveyard” of embattled or failed proteomics companies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.